40 related articles for article (PubMed ID: 32034953)
1. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Strumberg D; Scheulen ME; Schultheis B; Richly H; Frost A; Büchert M; Christensen O; Jeffers M; Heinig R; Boix O; Mross K
Br J Cancer; 2012 May; 106(11):1722-7. PubMed ID: 22568966
[TBL] [Abstract][Full Text] [Related]
2. Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.
Fujita K; Taguchi D; Fukuda K; Yoshida T; Shimazu K; Shinozaki H; Shibata H; Miura M
Invest New Drugs; 2024 Jun; 42(3):252-260. PubMed ID: 38517650
[TBL] [Abstract][Full Text] [Related]
3. Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.
Ono K; Murase R; Matsumoto N; Kubota Y; Ishida H; Fujita KI
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38459188
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Methioninase Lowers the Effective Dose of Regorafenib Against Colon-Cancer Cells: A Strategy for Widespread Clinical Use of a Toxic Drug.
Choobin BB; Kubota Y; Han Q; Ardjmand D; Morinaga S; Mizuta K; Bouvet M; Tsunoda T; Hoffman RM
Cancer Diagn Progn; 2023; 3(6):655-659. PubMed ID: 37927805
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Pharmacokinetics and Pharmacodynamics of Chemotherapeutics within a Spatial SILAC-Labeled Spheroid Model System.
Beller NC; Wang Y; Hummon AB
Anal Chem; 2023 Aug; 95(30):11263-11272. PubMed ID: 37462741
[TBL] [Abstract][Full Text] [Related]
6. Associations of HLA-C*01:02 and HLA-B*46:01 with regorafenib-induced erythema multiforme in Japanese patients with metastatic colorectal cancer.
Fujita KI; Matsumoto N; Murase R; Takeshima K; Ishida H; Kubota Y
Clin Transl Sci; 2023 Oct; 16(10):1741-1747. PubMed ID: 37424405
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer.
Yuan T; Wu R; Wang W; Liu Y; Kong W; Yang B; He Q; Zhu H
Front Pharmacol; 2023; 14():1136114. PubMed ID: 37138847
[No Abstract] [Full Text] [Related]
8. Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.
Rousseau B; Boukerma AK; Henriques J; Cohen R; Lucidarme O; Borg C; Tournigand C; Kim S; Bachet JB; Mazard T; Louvet C; Chibaudel B; Vernerey D; Andre T; Hulin A
Eur J Cancer; 2022 Jun; 168():99-107. PubMed ID: 35489233
[TBL] [Abstract][Full Text] [Related]
9. Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.
Arai J; Otoyama Y; Fujita KI; Goto K; Tojo M; Katagiri A; Nozawa H; Kubota Y; Takahashi T; Ishida H; Tsunoda T; Matsumoto N; Ogawa K; Nakagawa R; Muroyama R; Kato N; Yoshida H
BMC Cancer; 2022 Apr; 22(1):428. PubMed ID: 35443621
[TBL] [Abstract][Full Text] [Related]
10. Association Between Regorafenib Dose and Efficacy Against Metastatic Colorectal Cancer in a Real-World Setting.
Hatori M; Kawakami K; Wakatsuki T; Shinozaki E; Kobayashi K; Aoyama T; Nakano Y; Suzuki K; Yamaguchi K; Hama T
Dose Response; 2021; 19(4):15593258211047658. PubMed ID: 34675759
[TBL] [Abstract][Full Text] [Related]
11. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers.
Kobayashi K; Sugiyama E; Shinozaki E; Wakatsuki T; Tajima M; Kidokoro H; Aoyama T; Nakano Y; Kawakami K; Hashimoto K; Suenaga M; Ichimura T; Ogura M; Chin K; Nakayama I; Ooki A; Takahari D; Suzuki W; Yokokawa T; Minowa Y; Hiraoka T; Suzuki K; Sato H; Hama T; Yamaguchi K
Cancer Chemother Pharmacol; 2021 Jun; 87(6):767-777. PubMed ID: 33635392
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Taguchi D; Inoue M; Fukuda K; Yoshida T; Shimazu K; Fujita K; Okuyama H; Matsuhashi N; Tsuji A; Yoshida K; Miura M; Shibata H
Int J Clin Oncol; 2020 Apr; 25(4):531-540. PubMed ID: 31807967
[TBL] [Abstract][Full Text] [Related]
13. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib in the treatment of metastatic colorectal cancer.
de la Fouchardière C
Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib: A Review in Metastatic Colorectal Cancer.
Dhillon S
Drugs; 2018 Jul; 78(11):1133-1144. PubMed ID: 29943375
[TBL] [Abstract][Full Text] [Related]
16. Higher Systemic Exposure to Unbound Active Metabolites of Regorafenib Is Associated With Short Progression-Free Survival in Colorectal Cancer Patients.
Kubota Y; Fujita KI; Takahashi T; Sunakawa Y; Ishida H; Hamada K; Ichikawa W; Tsunoda T; Shimada K; Masuo Y; Kato Y; Sasaki Y
Clin Pharmacol Ther; 2020 Sep; 108(3):586-595. PubMed ID: 32034953
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
